China's NDRC said high-end manufacturing, the smart economy and modern services
contributed more than 40% to GDP growth in Q1–Q3; overall macro growth remained
within a reasonable range. The commission reported outbound technology licensing
for innovative drugs at about $130 billion in the first three quarters, close to
last year's full-year total, and said economic resilience has strengthened,
citing secure grain and energy procurement chains and effective mitigation of
frequent natural disasters.
